Q-omics provides the consensus-scored SYNJ2BP-COX16 profile across patient tissues and cancer cell-line models. SYNJ2BP-COX16 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SYNJ2BP-COX16 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SYNJ2BP-COX16 RNA expression shows 18,904 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where SYNJ2BP-COX16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNJ2BP-COX16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNJ2BP-COX16 survival associations across molecular data types. SYNJ2BP-COX16 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNJ2BP-COX16 RNA expression–survival associations across cancer types. High SYNJ2BP-COX16 expression shows unfavorable associations in ACC, MESO, UCEC, LUAD and DLBC, but favorable associations in CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SYNJ2BP-COX16 RNA expression.
This table summarizes SYNJ2BP-COX16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SYNJ2BP-COX16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNJ2BP-COX16 shows lower tumor expression in BLCA, BRCA, LUSC, STAD and COAD and higher tumor expression in HNSC. The BLCA box plot shows higher SYNJ2BP-COX16 RNA expression in normal versus tumor tissue (log2 FC = −0.518, t-test p < 0.001).
This table shows molecular features associated with SYNJ2BP-COX16 in patient tissues and cancer cell lines. In patient samples, SYNJ2BP-COX16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNJ2BP-COX16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
